Epicardial adipose tissue density is a better predictor of cardiometabolic risk in HFpEF patients: a prospective cohort study

Epicardial adipose tissue density is a better predictor of cardiometabolic risk in HFpEF patients: a prospective cohort study

Abstract Background Epicardial adipose tissue (EAT) accumulation is associated with multiple cardiometabolic risk factors and prognosis of heart failure with preserved ejection fraction (HFpEF). The correlation between EAT density and cardiometabolic risk and the effect of EAT density on clinical ou...

Full description

Bibliographic Details
Main Authors:	Jie Liu, Qi Yu, Ziyang Li, Yujiao Zhou, Zhiqiang Liu, Linna You, Li Tao, Qian Dong, Ziyu Zuo, Lei Gao, Dongying Zhang
Format:	Article
Language:	English
Published:	BMC 2023-03-01
Series:	Cardiovascular Diabetology
Subjects:	HFpEF Epicardial adipose tissue Adipose tissue density Cardiometabolic risk Heart failure readmission Mortality
Online Access:	https://doi.org/10.1186/s12933-023-01778-8

Similar Items

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
by: Norman Mangner, et al.
Published: (2023-10-01)

Structural and Hemodynamic Changes of the Right Ventricle in PH-HFpEF
by: Maria Barilli, et al.
Published: (2022-04-01)

Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond
by: Paolo Morfino, et al.
Published: (2022-08-01)

Diagnostic signature for heart failure with preserved ejection fraction (HFpEF): a machine learning approach using multi-modality electronic health record data
by: Nazli Farajidavar, et al.
Published: (2022-12-01)

Nitric oxide metabolites: associations with cardiovascular biomarkers and clinical parameters in patients with HFpEF
by: Karsten Piatek, et al.
Published: (2022-12-01)

A New Medical Decision Support System for Diagnosing HFrEF and HFpEF Using ECG and Machine Learning Techniques
by: Pinar Ozen Kavas, et al.
Published: (2022-01-01)

Incidence and causal association of functional atrial mitral regurgitation in HFpEF
by: Nikos T. Kouris, et al.
Published: (2023-01-01)

Obesity, Preserved Ejection Fraction Heart Failure, and Left Ventricular Remodeling
by: Jason Stencel, et al.
Published: (2023-05-01)

Targeting Collagen Pathways as an HFpEF Therapeutic Strategy
by: Alice Bonanni, et al.
Published: (2023-09-01)

Leucine Supplementation Improves Diastolic Function in HFpEF by HDAC4 Inhibition
by: Paula Ketilly Nascimento Alves, et al.
Published: (2023-11-01)

Does the Measurement of Ejection Fraction Still Make Sense in the HFpEF Framework? What Recent Trials Suggest
by: Alberto Palazzuoli, et al.
Published: (2023-01-01)

Effects of different exercise programs on the cardiorespiratory reserve in HFpEF patients: a systematic review and meta-analysis
by: Aristi Boulmpou, et al.
Published: (2022-03-01)

Dynamic aspects of ventricular interaction during exercise in HFpEF and in pre‐capillary pulmonary hypertension
by: Mathias Claeys, et al.
Published: (2023-02-01)

PINK1 Phosphorylates Drp1<sup>S616</sup> to Improve Mitochondrial Fission and Inhibit the Progression of Hypertension-Induced HFpEF
by: Jian Shou, et al.
Published: (2022-10-01)

Aortic flow is abnormal in HFpEF [version 2; peer review: 2 approved]
by: Pankaj Garg, et al.
Published: (2024-03-01)

Leucine Supplementation Prevents the Development of Skeletal Muscle Dysfunction in a Rat Model of HFpEF
by: Paula Ketilly Nascimento Alves, et al.
Published: (2024-03-01)

Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF
by: Antje Schauer, et al.
Published: (2021-03-01)

Longitudinal association between N-terminal B-type natriuretic peptide, anxiety and social support in patients with HFpEF: results from the multicentre randomized controlled Aldo-DHF trial
by: Marieke R. Wilke, et al.
Published: (2023-04-01)

Saturated Fatty Acid Blood Levels and Cardiometabolic Phenotype in Patients with HFpEF: A Secondary Analysis of the Aldo-DHF Trial
by: Katharina Lechner, et al.
Published: (2022-09-01)

Hydrogen Sulfide as a Potential Therapy for Heart Failure—Past, Present, and Future
by: Kyle B. LaPenna, et al.
Published: (2021-03-01)

Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls
by: Peter Jirak, et al.
Published: (2020-04-01)

Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA
by: Chao Chen, et al.
Published: (2024-03-01)

Unveiling the vulnerability of C57BL/6J female mice to HFpEF and its related complications
by: B. Srinivas, et al.
Published: (2024-03-01)

Empagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model
by: Ephraim B. Winzer, et al.
Published: (2022-09-01)

Aldehyde Dehydrogenase 2 Activator Augments the Beneficial Effects of Empagliflozin in Mice with Diabetes-Associated HFpEF
by: Guodong Pan, et al.
Published: (2022-09-01)

FBXL4 protects against HFpEF through Drp1-Mediated regulation of mitochondrial dynamics and the downstream SERCA2a
by: Miyesaier Abudureyimu, et al.
Published: (2024-04-01)

EAT Thickness as a Predominant Feature for Evaluating Arterial Stiffness in Patients with Heart Failure with Preserved Ejection Fraction
by: Liu Z, et al.
Published: (2022-04-01)

Webtool to enhance the accuracy of diagnostic algorithms for HFpEF: a prospective cross‐over study
by: Jerremy Weerts, et al.
Published: (2023-12-01)

Prognostic Value of Characterizing Myocardial Tissue by Cardiac MRI with T1 Mapping in HFpEF Patients: A Systematic Review and Meta-Analysis
by: Elena Golukhova, et al.
Published: (2022-04-01)

Inflammation as a therapeutic target in heart failure with preserved ejection fraction
by: Zhen Hui Peh, et al.
Published: (2023-06-01)

Association between prehypertension and epicardial adipose tissue thickness
by: Serpil Eroğlu
Published: (2014-06-01)

Epicardial adiposity as a predictor of COVID-19 severity in overweight and obese patients
by: M. A. Druzhilov, et al.
Published: (2022-04-01)

Heart Failure with Preserved Ejection Fraction (HFpEF): Part 2 Review of Experience and Evidence with SGLT-2 Inhibitors and Commentary
by: Soneil Guptha, Eteri Tsetskhladze
Published: (2023-06-01)

Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility
by: Volker Adams, et al.
Published: (2022-06-01)

Heart Failure with Preserved Ejection Fraction (HFpEF): Part 1 Review of Experience and Evidence in PARAGON-HF with Commentary
by: Soneil Guptha; Eteri Tsetskhladze
Published: (2023-07-01)

Role of Epicardial Adipose Tissue Secretome on Cardiovascular Diseases
by: Sara Leo, et al.
Published: (2023-06-01)

De Novo Lipogenesis-Related Monounsaturated Fatty Acids in the Blood Are Associated with Cardiovascular Risk Factors in HFpEF Patients
by: Matthias Bock, et al.
Published: (2023-07-01)

Browning Epicardial Adipose Tissue: Friend or Foe?
by: Elisa Doukbi, et al.
Published: (2022-03-01)

Stereological Estimation of Myocardial Fat and Its Associations with Obesity, Epicardial, and Visceral Adipose Tissue
by: Pernille Heimdal Holm, et al.
Published: (2022-10-01)

The role of coronary microvascular dysfunction in the pathogenesis of heart failure with preserved ejection fraction
by: Becker Al-Khayatt, et al.
Published: (2024-05-01)